news

Just when you thought you selected the right skin brightener & even toner!

Under the recent FDA stated CARES act Hydroquinone is not considered as GRAS and has also been classified as Drug Category II
(For more information, visit the website at:
https://www.jdsupra.com/legalnews/congress-enacts-otc-monograph-reform-96907/

Sytheon introduced Synovea® HR (INCI: Hexylresorcinol) as a safer and efficacious alternative to Hydroquinone in 2006. Synovea® HR is the optimal tool for addressing hyperpigmentation and globally approved. HR’s performance is superior to hydroquinone: reducing melanogenesis in primary human melanocytes, murine melanoma cells, and pigmented human epidermal equivalents. Several independent clinical studies have deemed Synovea® HR as the gold standard in skin brightening and even toning products demonstrating an efficacy of 2 to 4 times that of hydroquinone. Synovea® HR is effective on all skin types in addressing different types of pigmentation concerns. Hexylresorcinol itself has a long history of human use, well over 80 years, in a number of therapeutic and non-therapeutic applications, with more than 14 years in topical applications. Hexylresorcinol enjoys the GRAS designation and is being used in the food industry for, among other applications, shrimp preservation, and in the personal care industry as an antiseptic in, among other products, throat lozenges and wound cleansers. Recently, HR has been incorporated into several kinds of biomaterials for tissue healing and regeneration thereby strengthening the safety profile of the product.   Stay tuned for a clinical study update on “Split-body comparison between Hydroquinone and Hexylresorcinol”

For more information, please send your inquiry to info@sytheonltd.com

Sytheon’s CEO to Speak at NYSCC Acne Care Symposium

Sytheon’s CEO to Speak at NYSCC Acne Care Symposium

Ratan K. Chaudhuri, Ph.D., President and CEO at Sytheon, will discuss key strategic targets for mitigating acne-affected skin. Sytheon, a...

by Drew FrantzenMay 19, 2023
Read More
Sytheon is excited to announce a publication on Synergistic…

Sytheon is excited to announce a publication on Synergistic…

Sytheon is excited to announce a publication on Synergistic Anti-Inflammatory Effects of Isosorbide Fatty Acid Diesters in Cytokine-Induced Tissue Culture...

by hostingagencyusDecember 6, 2022
Read More
Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10…

Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10…

Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10 inspiring business leader by Inc. magazine to...

by hostingagencyusOctober 6, 2022
Read More
Sytenol® A is Accepted for Use in the Chinese Market

Sytenol® A is Accepted for Use in the Chinese Market

We are pleased to announce that Sytenol® A (Bakuchiol) has been successfully notified as a medium-low risk new cosmetic ingredient...

by hostingagencyusAugust 31, 2022
Read More
Sytheon Announces Relocation and Expansion of New Corporate Headquarters

Sytheon Announces Relocation and Expansion of New Corporate Headquarters

Sytheon relocates its headquarters to 10 Waterview Blvd, Parsippany, NJ. The move to a new state-of-the-art facility stems from Sytheon’s...

by hostingagencyusAugust 1, 2022
Read More
Bakuchiol – A natural alternative to Retinol shows holistic treatment approach…

Bakuchiol – A natural alternative to Retinol shows holistic treatment approach…

Bakuchiol – A natural alternative to Retinol shows holistic treatment approach for facial aging based on its multidirectional activity Beiersdorf...

by hostingagencyusJune 3, 2022
Read More